Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 67 for “"Fulvestrant"”.

  1. Zelluläre Mechanismen der Fulvestrant-induzierten Reorganisation von Adherens Junctions in Brustkrebszellen

    … Karzinome hemmen. Das Antiöstrogen Fulvestrant führt in vitro in Mammakarzinomzellen zu einer Reorganisation von Adherens Junctions (AJs) und E-Cadherin. Diese Strukturen, die eng in die Epithelial-Mesenchymale-Transition (EMT) involviert sind, haben direkte Implikationen für die …

    fu-berlin Repository record for Zelluläre Mechanismen der Fulvestrant-induzierten Reorganisation von Adherens Junctions in Brustkrebszellen (opens in a new tab)

  2. Preferential Estrogen Receptor β Ligands Inhibit Proliferation and Reduce Bcl-2 Expression in Fulvestrant-resistant Breast Cancer Cells

    Endocrine resistance is a significant clinical problem in the treatment of estrogen (E2) receptor positive breast cancers. There are two ER subtypes, ERα and ERβ, which promote and inhibit breast cancer cell proliferation respectively. While ER positive breast cancers typically express a high ratio …

    ottawa-retro Repository record for Preferential Estrogen Receptor β Ligands Inhibit Proliferation and Reduce Bcl-2 Expression in Fulvestrant-resistant Breast Cancer Cells (opens in a new tab)

  3. Economic evaluation of capivasertib as a second-line therapy for advanced breast cancer

    … the approved combination of capivasertib with fulvestrant for either all patients or only postmenopausal women offers better value for money relative to fulvestrant monotherapy. Next, we performed a budget impact analysis from healthcare third-party payer perspective that estimated cost …

    manitoba Repository record for Economic evaluation of capivasertib as a second-line therapy for advanced breast cancer (opens in a new tab)

  4. BET INHIBITION AS A STRATEGY FOR ENHANCING THE RESPONSE TO ESTROGEN ANTAGONISM/CDK4-6 INHIBITION IN ER POSITIVE BREAST CANCER

    … agents. Initially, we showed that Fulvestrant plus Palbociclib, one standard care of therapy, induces autophagy; therefore, we hypothesized that autophagy inhibition could increase the effectiveness of this combination. However, autophagy inhibition either genetically our …

    vcu Repository record for BET INHIBITION AS A STRATEGY FOR ENHANCING THE RESPONSE TO ESTROGEN ANTAGONISM/CDK4-6 INHIBITION IN ER POSITIVE BREAST CANCER (opens in a new tab)

  5. Escaping the Endosome with Colloidal Drug Aggregates

    … colloidal lapatinib by co-aggregation with fulvestrant, a non-ionizable drug, and either an amphiphilic block copolymer or the protein transferrin. Lapatinib, but not fulvestrant, was rapidly released from these colloids at endosomal pH. Furthermore, the cytotoxic effect of lapatinib was …

    toronto-retro Repository record for Escaping the Endosome with Colloidal Drug Aggregates (opens in a new tab)

  6. Targeting The Erβ/Her Oncogenic Network In Lung Cancer: Synergistic Antitumor Interaction And Potentiation Of Anti-Pd1 Efficacy

    … Targeting ER signaling with the antiestrogen fulvestrant has shown moderate activities in preclinical models of lung cancer. The reciprocal interaction between ER and EGFR could limit the activity of using anti-ER agent alone. In a phase II clinical trial, combining fulvestrant with the …

    umn Repository record for Targeting The Erβ/Her Oncogenic Network In Lung Cancer: Synergistic Antitumor Interaction And Potentiation Of Anti-Pd1 Efficacy (opens in a new tab)

  7. Co-delivery of Ionizable Colloid Forming Drugs with Therapeutic Nucleic Acids

    … ionizable analogs of the colloid-forming drug fulvestrant were formulated with siRNA. A subset of fulvestrant analogs could encapsulate siRNA and knockdown firefly luciferase in reporter cells in a pKa-dependent manner. Using the best performing fulvestrant analog, phospholipid and formulation …

    toronto-retro Repository record for Co-delivery of Ionizable Colloid Forming Drugs with Therapeutic Nucleic Acids (opens in a new tab)

  8. Evaluating Oral Selective Estrogen Receptor Degraders as Therapy for Endocrine Resistant ER+ Breast Cancer

    … this study, we compare a panel of oral SERDs to fulvestrant, both as monotherapies and with combinatorial agents, using viability assays to assess their efficacy on known mechanisms of resistance in invasive ductal and lobular carcinoma models. We determined that oral SERDs vary in ER degradation …

    jhu Repository record for Evaluating Oral Selective Estrogen Receptor Degraders as Therapy for Endocrine Resistant ER+ Breast Cancer (opens in a new tab)

  9. Epigenetic mechanisms of acquired endocrine resistance in an in vitro model of breast cancer

    … growth. They retain sensitivity to tamoxifen and fulvestrant. LCC9 cells, derived from LCC1 cells by growing them in increasing concentrations of fulvestrant, are completely estrogen-independent and are resistant to fulvestrant and cross-resistant to tamoxifen. When compared to MCF7 cells, LCC1 …

    edinburgh Repository record for Epigenetic mechanisms of acquired endocrine resistance in an in vitro model of breast cancer (opens in a new tab)

  10. Modulation of Epigenetic Regulatory Pathways as a Therapeutic Strategy in Breast Cancer

    … observation that breast tumor cells arrested by Fulvestrant + Palbociclib enter into states of both autophagy and senescence from which a subpopulation ultimately escapes, potentially contributing to recurrent disease. Autophagy inhibition utilizing pharmacologic or genetic approaches only …

    vcu Repository record for Modulation of Epigenetic Regulatory Pathways as a Therapeutic Strategy in Breast Cancer (opens in a new tab)

  11. Modulating ER And PPAR Pathways In Tumor Cells: The Effect On Macrophage Activation State And Pro- Tumor Function.

    … macrophages, an estrogen receptor inhibitor like Fulvestrant can be used to avoid ER signaling, shifting the macrophages more to the M1 like/ pro-inflammatory phase. It is still not clear how ER and PPAR pathways are modulated in macrophages and lung tumor cells. We investigated the levels of M1 …

    umn Repository record for Modulating ER And PPAR Pathways In Tumor Cells: The Effect On Macrophage Activation State And Pro- Tumor Function. (opens in a new tab)

  12. Imaging of breast cancer using SERS and SESORS

    … was also used for investigating the efficacy of fulvestrant, the first-in-class approved selective estrogen receptor degrader (SERD). The results confirmed that ER?-AuNPs can be used as a tool for identifying and characterising different breast cancer cells, based on ER? expression, and informing …

    strathclyde Repository record for Imaging of breast cancer using SERS and SESORS (opens in a new tab)

  13. Alterations at the cell membrane of breast cancer cells by estrogens and antiestrogens

    … studied the impact of the clinical antiestrogen Fulvestrant on AJs using the MCF-7/vBOS breast cancer cell line. ERα inhibition by Fulvestrant did not change E-cadherin expression but induced a distinct reorganization of E-cadherin-mediated AJs. The effect of Fulvestrant and other antiestrogens …

    fu-berlin Repository record for Alterations at the cell membrane of breast cancer cells by estrogens and antiestrogens (opens in a new tab)

  14. Targeting the PPARγ and ER pathways via modulation of inflammation in the tumor microenvironment: a novel lung cancer prevention strategy

    … prevention. Furthermore, anti-estrogens such as fulvestrant, a complete ER antagonist, have shown anti-tumorigenic activity in lung cancer and others such as tamoxifen have already been successfully implemented in both primary and secondary breast cancer prevention modalities. Preclinical and …

    umn Repository record for Targeting the PPARγ and ER pathways via modulation of inflammation in the tumor microenvironment: a novel lung cancer prevention strategy (opens in a new tab)

  15. Targeting estrogen receptor and ERBB kinases in non-small cell lung cancer

    … dacomitinib, and estrogen receptors with fulvestrant showed an enhanced inhibitory effect against HER receptors and their downstream signaling. Interestingly, we observed that inhibiting either pathways led to upregulation of the other indicating a compensatory mechanism has taken place. …

    umn Repository record for Targeting estrogen receptor and ERBB kinases in non-small cell lung cancer (opens in a new tab)

  16. Mathematical Modeling of Therapies for MCF7 Breast Cancer Cells

    … mimics the effects of an aromatase inhibitor, or fulvestrant, an ER degrader. These data were used to calibrate a mathematical model based on key interactions between ER signaling and the cell cycle. We show that the calibrated model is capable of predicting the combination treatment of …

    vt Repository record for Mathematical Modeling of Therapies for MCF7 Breast Cancer Cells (opens in a new tab)

  17. Exploiting Our Contemporary Understanding of the Molecular Pharmacology of the Estrogen Receptor to Develop Novel Therapeutics

    … selective estrogen receptor downregulator (SERD) fulvestrant, which is both a competitive antagonist and downregulator of ER, is often used to treat tumors progressing on AIs or tamoxifen. However, the unfavorable pharmacokinetic properties of this drug have largely limited its use as a …

    duke Repository record for Exploiting Our Contemporary Understanding of the Molecular Pharmacology of the Estrogen Receptor to Develop Novel Therapeutics (opens in a new tab)

  18. Investigating the Role of Androgen Receptor Signalling in Oestrogen Receptor Positive Breast Cancer

    … the inhibitory effect of the antioestrogen fulvestrant on BrCa proliferation. RNA-Seq analysis showed that the AR induces pathways linked to cellular proliferation, and becomes transcriptionally more active when ERα is inhibited by fulvestrant. Analysis of the transcriptional activity of AR …

    essex Download PDF for Investigating the Role of Androgen Receptor Signalling in Oestrogen Receptor Positive Breast Cancer (opens in a new tab)

Page 1 of 4